Results from the Phase 2 POLAR Trial: Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer
oncodaily - Pancreatic cancer remains one of the most challenging malignancies to treat, particularly in the metastatic setting, where immunotherapy has historically shown minimal activity. However, a biologically defined subset of patients […]
AI Summary: The Phase 2 POLAR trial presented results evaluating pembrolizumab combined with olaparib in homologous recombination–deficient metastatic pancreatic cancer, including safety, response rates and biomarker analyses. Investigators observed signals of activity in HRD‑selected patients, suggesting the immunotherapy–PARP inhibitor combination merits larger randomized testing rather than immediate headline glory.
Related Stories
Daraxonrasib’s ASCO moment sparks rapid clinical uptake for pancreatic cancer / 13 days
Daraxonrasib improves survival versus chemotherapy in metastatic pancreatic cancer / 5 wks
New drug doubles one-year survival in metastatic pancreatic cancer / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 5 wks
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 5 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Infectious Disease, Research Funding, Olfaction, Public Health and look for the RSS link.
StackHealth Time Machine